ReviewJGH open : an open access journal of gastroenterology and hepatology2021
Association of metabolic-associated fatty liver disease and risk of severe coronavirus disease 2019 illness.
Review in JGH open : an open access journal of gastroenterology and hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Magnetic Fields Affect Alcoholic Liver Disease by Liver Cell Oxidative Stress and Proliferation Regulation.Research (Washington, D.C.) · 2023Article
- COVID-19, adaptative immune response and metabolic-associated liver disease.Liver international : official journal of the International Association for the Study of the Liver · 2021Review
- Coronavirus disease 2019 and non-alcoholic fatty liver disease.World journal of hepatology · 2021Review
- Impact of COVID-19 on liver.World journal of clinical cases · 2021Review
- High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study.Endocrinology and metabolism (Seoul, Korea) · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the global health burden caused by the Coronavirus Disease 2019 (COVID-19), there have been numerous studies aimed to understand its clinical course and to determine risk factors that may impact prognosis. Pre-existing medical conditions are linked with COVID-19 severity, particularly cardiometabolic diseases. Increasing evidence has also linked metabolic-associated fatty liver disease (MAFLD) with severe COVID-19 illness. Thus, we review different published clinical data relating to the association of MAFLD and COVID-19 severity. Our review showed that published studies consistently support the association between MAFLD and more severe COVID-19, even after adjustment for confounding factors. It was also observed that an increasing hepatic fibrosis score is correlated with increasing severity of COVID-19. Finally, younger age and obesity among MAFLD patients also led to a greater risk of severe illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.